Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival

The impact of mononuclear cell infiltration on renal cell carcinoma (RCC) biology has been controversial, previously reported to be associated with either a favorable or unfavorable prognosis. The objective of the current study was to evaluate associations between mononuclear cell infiltration in routinely prepared paraffin‐embedded specimens with survival in patients with clear‐cell RCC.

[1]  P. Tripathi.  Nitric oxide and immune response. , 2007, Indian journal of biochemistry & biophysics.

[2]  J. Cheville,et al.  The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma , 2006, Cancer.

[3]  J. Cheville,et al.  Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma , 2005, Cancer.

[4]  A. Gramont,et al.  Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer , 2005 .

[5]  E. Van Cutsem,et al.  Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer , 2005, Oncology.

[6]  J. Cheville,et al.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2005, Cancer.

[7]  Hua Yu,et al.  Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects1 , 2005, The Journal of Immunology.

[8]  N. Restifo,et al.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.

[9]  M. Atkins,et al.  Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.

[10]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[11]  T. Zimmerman,et al.  Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells , 2004, Bone Marrow Transplantation.

[12]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[13]  D. McMillan,et al.  The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer , 2003, British Journal of Cancer.

[14]  M. Milowsky,et al.  Chemotherapeutic strategies for renal cell carcinoma. , 2003, The Urologic clinics of North America.

[15]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[16]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[17]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[18]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[19]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[20]  G. Zhu,et al.  Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine (2002) 8 (793-800)) , 2002 .

[21]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[22]  T. Igarashi,et al.  Effect of Tumor-Infiltrating Lymphocyte Subsets on Prognosis and Susceptibility to Interferon Therapy in Patients with Renal Cell Carcinoma , 2002, Urologia Internationalis.

[23]  R. Childs,et al.  Allogeneic stem cell transplantation for renal cell carcinoma , 2001, Current opinion in urology.

[24]  F. Marincola,et al.  Cytokines and Immune Response in the Tumor Microenvironment , 2001, Journal of immunotherapy.

[25]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[26]  C. Lowenstein,et al.  Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. , 2001, Cancer research.

[27]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Y. Soini,et al.  A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  G. Roos,et al.  Prognostic Significance of the Heidelberg Classification of Renal Cell Carcinoma , 1999, European Urology.

[30]  A. Strasser,et al.  The great escape: Is immune evasion required for tumor progression? , 1999, Nature Medicine.

[31]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[32]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[33]  S. Johansson,et al.  The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  R. Flanigan.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2006 .

[35]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[36]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.